Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
NEW YORK, Dec. 12, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Alexion Pharmaceuticals, Inc. (“Alexion Pharmaceuticals”) (NASDAQ:ALXN) between February 10, 2014 and November 9, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/alexion-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, Alexion made false and/or misleading statements and/or failed to disclose: (1) that the Company employed improper sales practices with respect to its product Soliris; (2) that the Company’s revenues from Soliris sales were unlikely to be sustainable; and (3) that as a result of the above, Alexion’s public statements were materially false and misleading at all relevant times.
On November 4, 2016, Alexion cancelled an appearance at the Credit Suisse Healthcare Conference. The Company also failed to file its Quarterly Report on Form 10-Q with the SEC within two days of its earnings announcement on October 27, 2016. On November 9, 2016, Alexion announced that the Company would not be able to timely file its financial and operating results for the quarter ended September 30, 2016. When this news was announced, shares of Alexion fell in value, causing investors harm.
If you suffered a loss in Alexion you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
